Auris Medical Holding Ltd EARS shares are trading higher by 12.7% at $4.16 Thursday morning after the company announced the acquisition of RNA therapeutics company Trasir Therapeutics and plans for strategic repositioning.
Auris Medical Holding is a clinical-stage biopharmaceutical company that develops therapeutics that address important unmet medical needs in neurotology, rhinology, allergy and CNS disorders.
Auris Medical has two projects in clinical development: Keyzilen for the treatment of acute inner ear tinnitus and Sonsuvi for the treatment of acute inner ear hearing loss. Its other product candidates are AM-125, AM-201, and AM-301. Auris Medical was founded in 1998 and is headquartered in Hamilton, Bermuda.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
